화학공학소재연구정보센터
홈 로그인 로그아웃 연락처 사이트맵
Polymer(Korea), Vol.25, No.3, 334-342, May, 2001
Export Citation
PHBV를 이용한 황산겐타마이신 서방성 제형의 제조와 방출거동
Preparation of Biodegradable PHBV Devices Containing Gentamicin Sulfate
최학수1, 김상욱1, 윤덕일2, 강길선1, 2, 이종문1, 2, 김용식3, 이해방4, †
  • 1전북대학교 고분자공학과
  • 2전북대학교 유기신물질공학과
  • 3가톨릭대학교 의과대학 정형외과
  • 4한국화학연구원 생체의료고분자연구팀
Hak Soo Choi1, Sang Wook Kim1, Duck-Il Yun2, Gilson Khang1, 2, John M. Rhee1, 2, Yong Sik Kim3, and Hai Bang Lee4, †
  • 1Department of Polymer and Technology, Chonbuk National University, 664-14, Dukjin, Chonju 561-756, Korea
  • 2Department of New Organic Materials Engineering, Chonbuk National University, 664-14, Dukjin, Chonju 561-756, Korea
  • 3Department of Orthopedic Surgery, Catholic University Medical School, Youido-dong, Youngdeungpo, Seoul 150-010, Korea
  • 4Biomaterials Laboratory, Korea Research Institute of Chemical Technology, P.O. Box 107, Yusung, Taejon 305-343, Korea
E-mail:
초록
항생제의 서방형 전달을 위해 황산겐타마이신 gentamicin sulfate (GS)을 함유한 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) 제형을 제조하였다. 본 연구에서는 제형의 두께, hydroxyvalerate(HV) 농도, 초기 약물함유량 및 첨가제의 함유에 따른 약물 방출거동의 변화를 조사하였다. 전자주사현미경을 이용하여 제형의 표면형태와 매트릭스 내부 약물의 조성을 관찰한 결과 약물방출 전과 후 모두 거칠고 다공성인 형태를 가짐을 알 수 있었다. 또한, HV와 첨가제의 함량이 증가할수록 약물이 고분자 매트릭스에 더 조밀하게 배열함을 관찰하였고, 이러한 구조가 약물의 방출에 영향을 미침을 알았다. HPLC를 이용하여 약물의 방출량을 측정한 결과, 모든 제형이 복합적인 방출 경향을 나타내었고, 일부 매트릭스는 30일 동안 거의 영차에 가까운 방출거동을 보였다. 이상의 결과에서 우리는 제형의 두께, 고분자 매트릭스의 조성, 첨가제의 함유량 등을 조절함으로 약물 방출을 제어할 수 있음을 확인하였다.
Gentamicin sulfate(GS)-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) devices were prepared for controlled-release of antibiotics. In this study, the effects of thickness, hydroxyvalerate (HV) content, initial drug-loading ratio. and additive content on the release profile have been investigated. The morphology of devices was examined with scanning electron microscope(SEM) before and after in vitro release; their highly porous surface and cross-sectional were observed. It could be suggested that device would be affected by the packing of the HV and additive content, which would depend on their structure. A high performance liquid chromatography (HPLC) was used to detect and quantify the release of GS from the device. The drug release from all the devices showed biphasic release patterns. and some matrices released the incorporated antibiotic throughout 30 days with a near zero-order release rate. The release patterns were shown to be changed by altering the thickness. copolymer ratio, and additive content.
Keywords:Gentamicin Sulfate;PHBV;Controlled Release;Zero-Order Release Rate
  1. Schlossberg D, "Orthopeadiic Infection", Springer-Verlag, New York (1988)
  2. Coombs R, Fitzgerald RH, "Infection in the Orthopeadic Patient", Butterworths, Boston (1989)
  3. Mauduit J, Buhk N, Vert M, J. Control. Release, 23, 221 (1993) 
  4. Zhang X, Wyss P, Pichora D, Goosen MFA, J. Pharm. Pharmacol., 46, 718 (1994)
  5. Trippel SB, J. Bone Joint Surg, 68A, 1297 (1986)
  6. Khang G, Cho JC, Lee JW, Rhee JM, Lee HB, Bio-Med. Mater. Eng., 9(1), 49 (1999)
  7. Khang G, Cho JC, Rhee JM, Lee JS, Lee HB, Polym. Preprints, 40, 288 (1999)
  8. Cho JC, Khang G, Rhee JM, Kim YS, Lee JS, Lee HB, Korea Polym. J., 7(2), 79 (1999)
  9. Khang G, Lee JH, Lee JW, Cho JC, Lee HB, Korea Polym. J., 8(2), 80 (2000)
  10. Cho JC, Khang G, Choi HS, Rhee JM, Lee HB, Polym.(Korea), 24(5), 728 (2000)
  11. Lee HB, Khang G, Cho JC, Rhee JM, Lee JS, "Fentanyl-loaded PLGA Microsheres for Local Anesthesia", in "Controlled Drug Delivery; Designing Technologies for the Future", eds. by K. Park and R.J. Mrnsy, ACS Symp. Series 752, p. 385, ACS, Washington D.C. (2000)
  12. Okada H, Toguchi H, CRC Crit. Rev. Therap. Drug Carrier Syst., 12, 1 (1995)
  13. Sampath SS, Garvin K, Robinson DH, J. Pharm., 78, 165 (1992)
  14. Firsov AA, Navarov AD, Fomina IP, Drug Dev. Ind. Pharm., 13, 1651 (1987)
  15. Bissery MC, Valeriote F, Thies C, "In vitro and in vivo, Evaluation of BCNU-loaded Microspheres Prepared from Poly((±)-lactide) and Poly((β-hydroxy-butyrate)", in "Microspheres and Drug Therapy", Pharmaceutical, Immunological and Medical Aspects, eds. by S.S. Davis, L. Illum, J.G. McVie, and Tomlinson, p. 217, Elsevier Sci., New York (1984)
  16. Juni K, Nakano M, CRC Crit. Rev. Therap. Drug Carrier Syst., 3, 209 (1987)
  17. Gogolewski S, Jovanoic M, Perren SM, Dillon JG, Hughes MK, J. Biomed. Mater. Res., 27, 1135 (1993) 
  18. Hocking PJ, Macromol. Chem. Phys., C32, 35 (1992)
  19. Gangrade N, Price JC, J. Microencapsul., 8, 185 (1991)
  20. Akhtar S, Pouton CW, Drug News Perspectives, 2, 89 (1989)
  21. Atkins TW, Peacock SJ, J. Microencapsul., 13(6), 709 (1996)
  22. Gursel I, Hasirci V, J. Microencapsul., 12(2), 185 (1995)
  23. Conway BR, Eyles JE, Alpar HO, J. Control. Release, 49, 1 (1997) 
  24. Koosa F, Muller RH, Davis SS, Davies MC, J. Control. Release, 9, 149 (1989) 
  25. Juni K, Nakano M, Kubota M, J. Control. Release, 4, 25 (1986) 
  26. Khang G, Choi HS, Rhee JM, Yoon SC, Cho JC, Lee HB, Korea Polym. J., 8(6), 253 (2000)
  27. Khang G, Kim SW, Cho JC, Rhee JM, Yoon SC, Lee HB, Bio-Med. Mater. Eng., in press (2000)
  28. Akhtar S, Pouton CW, Notarianni LJ, Gould PL, J. Pharm. Pharmacol., 40, 118 (1988)
  29. Iannuccelli V, Coppi G, Bondi M, Pinelli M, Mingione A, Cameroni R, Int. J. Pharm., 143, 187 (1996) 
  30. Sendil D, Gursel I, Wise DL, Hasirci V, J. Control. Release, 59, 207 (1999)